Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2014

View Archived Issues

Otsuka Pharmaceutical recaps highlights of second quarter of fiscal 2014

Trevena releases data from phase IIa/b study of TRV-130 in acute postoperative pain

ObsEva initiates phase II trial of oxytocin receptor antagonist in women undergoing embryo transfer

Wilson Therapeutics begins phase II study of WTX-101 in Wilson disease

Validation of the antifibrogenic activity of a peripherally restricted CB1 antagonist

First possible biomarker for liver disease in alpha-1 antitypsin deficiency identified

RALDH 1 explored as a target for treating obesity and diabetes

Trumenba launched in the U.S.

JCAR-015 leukemia T-cell therapy granted FDA orphan drug designation

Hemispherx's Ampligen blocks critical Ebola viral disease viral protein

P-11520031, a novel T-type calcium channel blocker for neuropathic pain

German organization reports development of anti-parasitic vaccines

The Vanderbilt University patents detail novel mAChR M1 PAMs

Ajinomoto patents glycogen synthase activators

Chong Kun Dang Holdings patent divulges novel HDAC6 inhibitors

Roche discloses new CB2 receptor agonists

Preclinical pharmacology, safety and activity profiling of dual JAK3/ITK inhibitor ARN-4079

Consortium readied to advance development of MicroNeurotrophins for ALS

Actavis completes tender offer for Durata Therapeutics

Investigators develop DNA-based vaccine against Leishmaniasis infection

Inderal approved in Japan for the inhibition of onset of hypoxic spell in RVOTO

Long-acting anticholinergic drug to treat bronchial asthma approved in Japan

Arrowhead Research seeks clearance for phase I trial of ARC-AAT for AAT deficiency

Reckitt Benckiser plans to spin off pharmaceuticals business into Indivior

European Commission grants marketing authorization to Harvoni

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...